Scan the QR code to request your copy of this case study
Please ensure you are already logged in to the Bayer UK RPS 2026 Meeting App
Prescribing information
UK prescribing information and adverse event reporting information for EYLEA® (aflibercept) 40 mg/mL and 114.3 mg/mL solution for injection is available via the QR codes below. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.
EYLEA® (aflibercept)
40 mg/mL
EYLEA® (aflibercept)
114.3 mg/mL
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Bayer plc. If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.Further information is available on the "contact" tab at www.bayer.co.uk.
Produced and funded by Bayer.
By scanning this QR code you authorise Bayer, as well as other Bayer AG Group companies, to directly deliver marketing communications to you through e-mails or other electronic communications. They may contain information about services, products or events and may also contain promotional content. Our use of your data, including the analysis of such communications, is described in more detail at data privacy (Privacy Statement for Healthcare Professionals (HCPs)) You are free to revoke your consent at any time with future effect by clicking an unsubscribe link in any Bayer electronic communication.